Preview Mode Links will not work in preview mode

Clinical Literature Summaries presented by InpharmD™ (S3)


Feb 8, 2021

A randomized, multicenter, double-blind, placebo-controlled, phase 1/2a clinical trial to evaluate the safety, reactogenicity, and immunogenicity of Ad26.COV2.S - a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike (S) protein